Glenmark Pharmaceuticals reported a consolidated net profit of Rs 354.5 crore for Q2 FY25, rebounding from a loss of Rs 180.3 crore in the same quarter last year. Revenue from operations increased by 7.1% to Rs 3,433 crore, driven by strong performances in the Indian and European markets, particularly in cardiac and dermatology sectors. Despite a slight revenue drop in North America, the company’s EBITDA grew by 30.2% to Rs 601.9 crore, with margins at 17.5%.
